Giovanni Veloz Irizarry, MD
Pulmonary Disease · Ponce, PRNPI 1144619230
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), education and speaking fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 28.8% of the total. Reporting peaked in 2024 at $4,523 and has fallen 51.5% since, to $2,194 in 2025. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $62.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Merck$2K
- AstraZeneca$2K
- GSK$953
- Boehringer Ingelheim$813
- Bayer$795
- plus $2K from 25 others
What the payments were for
- Consulting fees$2002%
- Speaking & faculty fees$1,50014%
- Food & beverage$5,98656%
- Education$3,01528%
- Gifts$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $3,093 |
| Merck | 5 | $1,627 |
| AstraZeneca | 41 | $1,520 |
| GSK | 33 | $953 |
| Boehringer Ingelheim | 19 | $813 |
| Bayer | 17 | $795 |
| Medtronic | 2 | $244 |
| United Therapeutics Corporation | 4 | $205 |
| Genentech USA, Inc. | 4 | $201 |
| Johnson & Johnson(2 entities) | 8 | $158 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Shire North American Group Inc | 1 | $98 |
| Lilly USA, LLC | 1 | $97 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Olympus Latin America, Inc. | 3 | $88 |
| Sanofi | 4 | $87 |
| Chiesi USA, Inc. | 3 | $86 |
| Mylan Specialty L.p. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Mylan LLC | 2 | $43 |
| AbbVie | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| Harmony Biosciences LLC | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $26 |
| Amgen | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Boston Scientific | 1 | $20 |
| PBG Puerto Rico LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,000
- PNEUMOVAX 23$1,500
- Adempas$574
- TEZSPIRE$375
- FASENRA$370
- TRELEGY ELLIPTA$250
- OFEV$244
- NUCALA$225
- ILLUMISITE$166
- TYVASO$125
- ELIQUIS$124
How this compares
$10,752 in reported general payments places this provider in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 19 | $261,745 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $17,858 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,298 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $5,739 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $2,210 |
| Fluticasone Propionate | 28 | $454 |
| Montelukast Sodium | 43 | $323 |
| Famotidine | 21 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $795 | $261,74519 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $953 | $27,15657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- George FahedPonce$16K
- Dev Boodoosingh CasianoPonce$10K
- Jesse Aleman-OrtizPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Sandra Galarza-VargasPonce$7K
- Ilean Lamboy HernandezPonce$5K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.